These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12857042)

  • 1. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies.
    Takano H; Hasegawa H; Nagai T; Komuro I
    Intern Med; 2003 Jun; 42(6):465-9. PubMed ID: 12857042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy.
    Remme WJ
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):349-60. PubMed ID: 14618097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure.
    Reis Filho JR; Cardoso JN; Cardoso CM; Pereira-Barretto AC
    Arq Bras Cardiol; 2015 Jun; 104(6):502-6. PubMed ID: 26131706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ventricular remodeling in heart failure clinical trials.
    Kirkpatrick JN; St John Sutton M
    Curr Heart Fail Rep; 2012 Dec; 9(4):328-36. PubMed ID: 22983907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodeling in systolic heart failure: therapeutic implications.
    Chatterjee K
    Indian Heart J; 2004; 56(2):99-109. PubMed ID: 15377130
    [No Abstract]   [Full Text] [Related]  

  • 8. Matrix metallopropteinases in heart failure.
    Tousoulis D; Kampoli AM; Papageorgiou N; Antoniades C; Siasos G; Latsios G; Tsiamis E; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1181-91. PubMed ID: 22519448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental options in the treatment of heart failure: the role of cytokine antagonism.
    Kalra D; Bozkurt B; Deswal A; Torre-Amione G; Mann DL
    Heart Fail Monit; 2001; 1(4):114-21. PubMed ID: 12634895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the relationship between ischemia and congestive heart failure.
    Remme WJ
    Clin Cardiol; 2000 Jul; 23(7 Suppl 4):IV4-8. PubMed ID: 10894449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling as an end-point in heart failure therapy.
    Cohn JN
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):7-8. PubMed ID: 15228052
    [No Abstract]   [Full Text] [Related]  

  • 15. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac fibroblasts: at the heart of myocardial remodeling.
    Porter KE; Turner NA
    Pharmacol Ther; 2009 Aug; 123(2):255-78. PubMed ID: 19460403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
    Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
    Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.